MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to address safety and efficiency of a new iron particle contrast
agent, ferumoxytol. This product may be more useful in viewing the vessels of the brain and
areas in the brain on magnetic resonance imaging (MRI), or magnetic resonance angiography
(MRA), than the standard substance, gadolinium, injected during MRI and MRA.
Other ways in which ferumoxytol may help include the following:
1. Ferumoxytol may provide the ability to better see inflammatory lesions on magnetic
resonance imaging (MRI) scans
2. Ferumoxytol may be useful in its ability to cross blood vessels into inflammatory
processes, and
3. Ferumoxytol, because of its size and ability to get into the area next to your
inflammatory lesion and could assist in the treatment of inflammatory lesions
association with cardiac surgery or CNS vascular surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Oregon Health and Science University
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)